查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1591979

免疫腫瘤檢測市場：按適應症、按產品、按技術、按應用分類 - 2025-2030 年全球預測

Immuno Oncology Assays Market by Indication (Bladder Cancer, Colorectal Cancer, Lung Cancer), Product (Consumables, Software), Technology, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年免疫腫瘤檢測市場價值為62.6億美元，預計到2024年將達到72.1億美元，複合年成長率為15.26%，到2030年將達到169.3億美元。

免疫腫瘤學測試是重要的診斷工具，用於評估對癌症治療的免疫反應，並在個人化癌症治療中發揮重要作用。有必要監測和評估患者對免疫療法的反應，以確保更有效、更有針對性的癌症治療並改善治療結果。這些測定的應用包括識別生物標記、確定腫瘤中的免疫細胞浸潤以及最佳化新的治療方法。主要最終用戶包括實驗室、製藥公司和臨床診斷中心。癌症發病率的上升、免疫療法的日益普及以及精準醫療的進步正在推動市場成長。此外，政府對癌症研究的資助和生物標記發現的技術創新正在增強市場。最新的潛在商機在於擴大聯合治療和針對各種癌症類型的新生物標記的應用。為了抓住這些機會，建議投資先進技術，例如可以同時分析多種生物標記的多重測定。然而，市場擴張存在一些限制，包括減緩新檢測方法引入的監管障礙，以及限制採用率的高成本。此外，免疫反應的複雜性和患者之間的生物變異性也帶來了重大挑戰。創新和研究的一個主要領域是開發能夠提供更高靈敏度和特異性同時具有成本效益的檢測方法。與數位技術的整合，例如用於資料分析的人工智慧和改進的實驗室自動化，是一個有前途的前沿領域。該市場競爭激烈但又分散，現有參與者眾多，而新參與企業的興趣也與日俱增。持續的研發和策略夥伴關係關係對於促進知識交流和利用前沿發現、塑造免疫腫瘤學診斷的未來模式至關重要。

主要市場統計
基準年[2023] 62.6億美元
預測年份 [2024] 72.1億美元
預測年份 [2030] 169.3億美元
複合年成長率（%） 15.26%

市場動態：揭示快速發展的免疫腫瘤檢測市場的關鍵市場洞察

供需的動態交互作用正在改變免疫腫瘤學檢測市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 癌症發生率增加以及標靶治療相對於其他治療方法的採用
    • 開發生物資訊學工具以增強藥物開發過程
    • 醫療支出和醫療保險的增加
  • 市場限制因素
    • 不利的監管和報銷情況
  • 市場機會
    • 癌症治療技術與研發的進步
    • 伴同性診斷的出現
  • 市場挑戰
    • 缺乏操作設備的醫療保健專業

波特的五力：駕馭免疫腫瘤檢測市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解免疫腫瘤檢測市場的外部影響

外部宏觀環境因素在塑造免疫腫瘤檢測市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解免疫腫瘤檢測市場的競爭格局

免疫腫瘤檢測市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣免疫腫瘤檢測市場供應商的績效評估

FPNV定位矩陣是評估免疫腫瘤檢測市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了免疫腫瘤檢測市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，免疫腫瘤檢測市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 與其他治療方法相比，癌症發生率增加以及標靶治療的採用
      • 開發生物資訊學工具以增強藥物開發過程
      • 醫療費用和醫療保險的增加
    • 抑制因素
      • 不利的監管和報銷情況
    • 機會
      • 癌症治療技術與研發的進步
      • 伴同性診斷的出現
    • 任務
      • 缺乏操作設備的醫療保健專業人員
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章按適應症分類的免疫腫瘤檢測市場

  • 膀胱癌
  • 大腸直腸癌
  • 肺癌
  • 惡性黑色素瘤

第7章免疫腫瘤檢測市場：依產品

  • 消耗品
  • 軟體

第8章免疫腫瘤學檢測市場：依技術分類

  • 流式細胞技術
  • 免疫檢測
  • 次世代定序
  • 聚合酵素鏈鎖反應

第9章免疫腫瘤學檢測市場：依應用分類

  • 臨床診斷
  • 調查

第10章美洲免疫腫瘤檢測市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太免疫腫瘤檢測市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的免疫腫瘤檢測市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • BioAgilytix Labs, LLC
  • Charles River Laboratories International, Inc.
  • ElsaLys Biotech SA
  • Eurofins DiscoverX Products, LLC
  • HTG Molecular Diagnostics, Inc.
  • Illumina, Inc.
  • Merck KGaA
  • NanoString Technologies, Inc.
  • NeoGenomics Laboratories, Inc.
  • PerkinElmer, Inc.
  • QIAGEN GmbH
  • Sartorius AG
  • Thermo Fisher Scientific, Inc.
  • Twist Bioscience Corporation
Product Code: MRR-43676CF42882

The Immuno Oncology Assays Market was valued at USD 6.26 billion in 2023, expected to reach USD 7.21 billion in 2024, and is projected to grow at a CAGR of 15.26%, to USD 16.93 billion by 2030.

Immuno-oncology assays are critical diagnostic tools used to assess the immune response to cancer therapies, thus playing a crucial role in personalized cancer treatment. They are necessary for monitoring and evaluating patient responses to immunotherapies, ensuring more effective, targeted cancer treatments with improved outcomes. The application of these assays includes identifying biomarkers, determining immune cell infiltration in tumors, and optimizing novel therapeutic approaches. Predominant end-users include research laboratories, pharmaceutical companies, and clinical diagnostic centers. The growing prevalence of cancer, increasing adoption of immunotherapies, and advancements in precision medicine drive market growth. Furthermore, government funding in cancer research combined with technological innovations in biomarker discovery bolster the market. The latest potential opportunities lie in expanding applications in combination therapies and emerging biomarkers for various cancer types. To seize these opportunities, investment in advanced technologies like multiplexed assays that can concurrently analyze multiple biomarkers is recommended. However, market expansion faces several limitations, including high costs, which can restrain adoption rates, alongside regulatory hurdles that slow the introduction of new assays. Additionally, the complexity of immune responses and the biological variability between patients pose significant challenges. Key areas for innovation and research involve developing assays that offer higher sensitivity and specificity while being cost-effective. Integration with digital technologies, such as AI for data analysis and improved automation in labs, represents a promising frontier. The market is competitive yet fragmented, characterized by the presence of numerous established players and growing interest from new entrants, driving innovation and enhancing product offerings. Continuous R&D and strategic partnerships are essential to foster knowledge exchange and leverage cutting-edge discoveries, shaping the future landscape of immuno-oncology diagnostics.

KEY MARKET STATISTICS
Base Year [2023] USD 6.26 billion
Estimated Year [2024] USD 7.21 billion
Forecast Year [2030] USD 16.93 billion
CAGR (%) 15.26%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Immuno Oncology Assays Market

The Immuno Oncology Assays Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing incidences of cancer and adoption of targeted therapy over other treatment options
    • Development of bioinformatic tools enhancing the drug development process
    • Rise in healthcare expenditure and healthcare insurance
  • Market Restraints
    • Unfavorable regulatory and reimbursement scenario
  • Market Opportunities
    • Technological advancement and R&D for the treatment of cancer
    • Emergence of companion diagnostics
  • Market Challenges
    • Lack of healthcare professions for device operation

Porter's Five Forces: A Strategic Tool for Navigating the Immuno Oncology Assays Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Immuno Oncology Assays Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Immuno Oncology Assays Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Immuno Oncology Assays Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Immuno Oncology Assays Market

A detailed market share analysis in the Immuno Oncology Assays Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Immuno Oncology Assays Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Immuno Oncology Assays Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Immuno Oncology Assays Market

A strategic analysis of the Immuno Oncology Assays Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Immuno Oncology Assays Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., BioAgilytix Labs, LLC, Charles River Laboratories International, Inc., ElsaLys Biotech S.A., Eurofins DiscoverX Products, LLC, HTG Molecular Diagnostics, Inc., Illumina, Inc., Merck KGaA, NanoString Technologies, Inc., NeoGenomics Laboratories, Inc., PerkinElmer, Inc., QIAGEN GmbH, Sartorius AG, Thermo Fisher Scientific, Inc., and Twist Bioscience Corporation.

Market Segmentation & Coverage

This research report categorizes the Immuno Oncology Assays Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indication, market is studied across Bladder Cancer, Colorectal Cancer, Lung Cancer, and Melanoma.
  • Based on Product, market is studied across Consumables and Software.
  • Based on Technology, market is studied across Flow Cytometry, Immunoassay, Next-Generation Sequencing, and Polymerase Chain Reaction.
  • Based on Application, market is studied across Clinical Diagnostics and Research.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing incidences of cancer and adoption of targeted therapy over other treatment options
      • 5.1.1.2. Development of bioinformatic tools enhancing the drug development process
      • 5.1.1.3. Rise in healthcare expenditure and healthcare insurance
    • 5.1.2. Restraints
      • 5.1.2.1. Unfavorable regulatory and reimbursement scenario
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancement and R&D for the treatment of cancer
      • 5.1.3.2. Emergence of companion diagnostics
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of healthcare professions for device operation
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Immuno Oncology Assays Market, by Indication

  • 6.1. Introduction
  • 6.2. Bladder Cancer
  • 6.3. Colorectal Cancer
  • 6.4. Lung Cancer
  • 6.5. Melanoma

7. Immuno Oncology Assays Market, by Product

  • 7.1. Introduction
  • 7.2. Consumables
  • 7.3. Software

8. Immuno Oncology Assays Market, by Technology

  • 8.1. Introduction
  • 8.2. Flow Cytometry
  • 8.3. Immunoassay
  • 8.4. Next-Generation Sequencing
  • 8.5. Polymerase Chain Reaction

9. Immuno Oncology Assays Market, by Application

  • 9.1. Introduction
  • 9.2. Clinical Diagnostics
  • 9.3. Research

10. Americas Immuno Oncology Assays Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Immuno Oncology Assays Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Immuno Oncology Assays Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Agilent Technologies, Inc.
  • 2. Bio-Rad Laboratories, Inc.
  • 3. BioAgilytix Labs, LLC
  • 4. Charles River Laboratories International, Inc.
  • 5. ElsaLys Biotech S.A.
  • 6. Eurofins DiscoverX Products, LLC
  • 7. HTG Molecular Diagnostics, Inc.
  • 8. Illumina, Inc.
  • 9. Merck KGaA
  • 10. NanoString Technologies, Inc.
  • 11. NeoGenomics Laboratories, Inc.
  • 12. PerkinElmer, Inc.
  • 13. QIAGEN GmbH
  • 14. Sartorius AG
  • 15. Thermo Fisher Scientific, Inc.
  • 16. Twist Bioscience Corporation

LIST OF FIGURES

  • FIGURE 1. IMMUNO ONCOLOGY ASSAYS MARKET RESEARCH PROCESS
  • FIGURE 2. IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. IMMUNO ONCOLOGY ASSAYS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. IMMUNO ONCOLOGY ASSAYS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. IMMUNO ONCOLOGY ASSAYS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. IMMUNO ONCOLOGY ASSAYS MARKET DYNAMICS
  • TABLE 7. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. IMMUNO ONCOLOGY ASSAYS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. IMMUNO ONCOLOGY ASSAYS MARKET, FPNV POSITIONING MATRIX, 2023